237 related articles for article (PubMed ID: 10589790)
1. Lysophosphatidic acid induces urokinase secretion by ovarian cancer cells.
Pustilnik TB; Estrella V; Wiener JR; Mao M; Eder A; Watt MA; Bast RC; Mills GB
Clin Cancer Res; 1999 Nov; 5(11):3704-10. PubMed ID: 10589790
[TBL] [Abstract][Full Text] [Related]
2. Macrophage colony-stimulating factor mediates invasion of ovarian cancer cells through urokinase.
Chambers SK; Wang Y; Gertz RE; Kacinski BM
Cancer Res; 1995 Apr; 55(7):1578-85. PubMed ID: 7882368
[TBL] [Abstract][Full Text] [Related]
3. Macrophage inhibitory cytokine-1 induces the invasiveness of gastric cancer cells by up-regulating the urokinase-type plasminogen activator system.
Lee DH; Yang Y; Lee SJ; Kim KY; Koo TH; Shin SM; Song KS; Lee YH; Kim YJ; Lee JJ; Choi I; Lee JH
Cancer Res; 2003 Aug; 63(15):4648-55. PubMed ID: 12907645
[TBL] [Abstract][Full Text] [Related]
4. Lysophospholipids increase interleukin-8 expression in ovarian cancer cells.
Schwartz BM; Hong G; Morrison BH; Wu W; Baudhuin LM; Xiao YJ; Mok SC; Xu Y
Gynecol Oncol; 2001 May; 81(2):291-300. PubMed ID: 11330965
[TBL] [Abstract][Full Text] [Related]
5. Quantitative RT-PCR assays for the determination of urokinase-type plasminogen activator and plasminogen activator inhibitor type 1 mRNA in primary tumor tissue of breast cancer patients: comparison to antigen quantification by ELISA.
Biermann JC; Holzscheiter L; Kotzsch M; Luther T; Kiechle-Bahat M; Sweep FC; Span PN; Schmitt M; Magdolen V
Int J Mol Med; 2008 Feb; 21(2):251-9. PubMed ID: 18204793
[TBL] [Abstract][Full Text] [Related]
6. Effect of bFGF on invasion of ovarian cancer cells through the regulation of Ets-1 and urokinase-type plasminogen activator.
Li T; Jiang S
Pharm Biol; 2010 Feb; 48(2):161-5. PubMed ID: 20645833
[TBL] [Abstract][Full Text] [Related]
7. Lysophosphatidic acid induction of urokinase plasminogen activator secretion requires activation of the p38MAPK pathway.
Estrella VC; Eder AM; Liu S; Pustilnik TB; Tabassam FH; Claret FX; Gallick GE; Mills GB; Wiener JR
Int J Oncol; 2007 Aug; 31(2):441-9. PubMed ID: 17611702
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of edg-2/vzg-1 induces apoptosis and anoikis in ovarian cancer cells in a lysophosphatidic acid-independent manner.
Furui T; LaPushin R; Mao M; Khan H; Watt SR; Watt MA; Lu Y; Fang X; Tsutsui S; Siddik ZH; Bast RC; Mills GB
Clin Cancer Res; 1999 Dec; 5(12):4308-18. PubMed ID: 10632375
[TBL] [Abstract][Full Text] [Related]
9. Reduced syndecan-1 expression stimulates heparin-binding growth factor-mediated invasion in ovarian cancer cells in a urokinase-independent mechanism.
Matsuzaki H; Kobayashi H; Yagyu T; Wakahara K; Kondo T; Kurita N; Sekino H; Inagaki K; Suzuki M; Kanayama N; Terao T
Oncol Rep; 2005 Aug; 14(2):449-57. PubMed ID: 16012729
[TBL] [Abstract][Full Text] [Related]
10. Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer.
Goetzl EJ; Dolezalova H; Kong Y; Hu YL; Jaffe RB; Kalli KR; Conover CA
Cancer Res; 1999 Oct; 59(20):5370-5. PubMed ID: 10537322
[TBL] [Abstract][Full Text] [Related]
11. Endothelin-1 induces tumor proteinase activation and invasiveness of ovarian carcinoma cells.
Rosanò L; Varmi M; Salani D; Di Castro V; Spinella F; Natali PG; Bagnato A
Cancer Res; 2001 Nov; 61(22):8340-6. PubMed ID: 11719468
[TBL] [Abstract][Full Text] [Related]
12. The human lipid phosphate phosphatase-3 decreases the growth, survival, and tumorigenesis of ovarian cancer cells: validation of the lysophosphatidic acid signaling cascade as a target for therapy in ovarian cancer.
Tanyi JL; Morris AJ; Wolf JK; Fang X; Hasegawa Y; Lapushin R; Auersperg N; Sigal YJ; Newman RA; Felix EA; Atkinson EN; Mills GB
Cancer Res; 2003 Mar; 63(5):1073-82. PubMed ID: 12615725
[TBL] [Abstract][Full Text] [Related]
13. Osteopontin induces increased invasiveness and plasminogen activator expression of human mammary epithelial cells.
Tuck AB; Arsenault DM; O'Malley FP; Hota C; Ling MC; Wilson SM; Chambers AF
Oncogene; 1999 Jul; 18(29):4237-46. PubMed ID: 10435636
[TBL] [Abstract][Full Text] [Related]
14. Profiling follicle stimulating hormone-induced gene expression changes in normal and malignant human ovarian surface epithelial cells.
Ho SM; Lau KM; Mok SC; Syed V
Oncogene; 2003 Jul; 22(27):4243-56. PubMed ID: 12833147
[TBL] [Abstract][Full Text] [Related]
15. Induction of protein growth factor systems in the ovaries of transgenic mice overexpressing human type 2 lysophosphatidic acid G protein-coupled receptor (LPA2).
Huang MC; Lee HY; Yeh CC; Kong Y; Zaloudek CJ; Goetzl EJ
Oncogene; 2004 Jan; 23(1):122-9. PubMed ID: 14712217
[TBL] [Abstract][Full Text] [Related]
16. The lysophosphatidic acid (LPA) receptors their expression and significance in epithelial ovarian neoplasms.
Wang P; Wu X; Chen W; Liu J; Wang X
Gynecol Oncol; 2007 Mar; 104(3):714-20. PubMed ID: 17204312
[TBL] [Abstract][Full Text] [Related]
17. Phorbol 12-myristate 13-acetate stimulates lysophosphatidic acid secretion from ovarian and cervical cancer cells but not from breast or leukemia cells.
Shen Z; Belinson J; Morton RE; Xu Y; Xu Y
Gynecol Oncol; 1998 Dec; 71(3):364-8. PubMed ID: 9887232
[TBL] [Abstract][Full Text] [Related]
18. Heregulin regulation of urokinase plasminogen activator and its receptor: human breast epithelial cell invasion.
Mazumdar A; Adam L; Boyd D; Kumar R
Cancer Res; 2001 Jan; 61(1):400-5. PubMed ID: 11196194
[TBL] [Abstract][Full Text] [Related]
19. Reduction of breast carcinoma tumor growth and lung colonization by overexpression of the soluble urokinase-type plasminogen activator receptor (CD87).
Krüger A; Soeltl R; Lutz V; Wilhelm OG; Magdolen V; Rojo EE; Hantzopoulos PA; Graeff H; Gänsbacher B; Schmitt M
Cancer Gene Ther; 2000 Feb; 7(2):292-9. PubMed ID: 10770639
[TBL] [Abstract][Full Text] [Related]
20. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
Hildenbrand R; Schaaf A
Int J Oncol; 2009 Jan; 34(1):15-23. PubMed ID: 19082473
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
